Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Elena Gabriela Chiorean

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3306-9592; OpenAlex author ID A5019995834, A5158630325. Sources: ClinicalTrials.gov.

Their work

Papers
54 (first author 3, last author 14)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
211
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 5 papers · 2014: 4 papers · 2015: 3 papers, 1 trial · 2016: 6 papers · 2017: 2 papers · 2018: 4 papers · 2019: 4 papers · 2020: 4 papers · 2021: 5 papers · 2022: 2 papers · 2023: 3 papers · 2024: 5 papers · 2025: 4 papers · 2026: 2 papers

Papers 50 of 54

  1. Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.3390/cancers18030507↗
  2. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  3. Long-Term Survival Following Chemoradiation in Locoregional Recurrent Germline ATM Mutated Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.adro.2025.101742↗
  4. ACR Appropriateness Criteria® Screening, Locoregional Assessment, and Surveillance of Pancreatic Ductal Adenocarcinoma: 2025 Update. Co-author DOI 10.1016/j.jacr.2025.08.037↗
  5. Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer. First author DOI 10.1016/j.suronc.2025.102268↗
  6. HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-2200↗
  7. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. Co-author DOI 10.1016/j.gassur.2023.12.022↗
  8. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.013↗
  9. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Co-author DOI 10.1093/oncolo/oyae210↗
  10. Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer. Last author DOI 10.1200/edbk_438598↗
  11. Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. Co-author DOI 10.6004/jnccn.2023.7099↗
  12. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic… Co-author DOI 10.1002/cam4.6621↗
  13. Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002253↗
  14. The role of molecular testing in pancreatic cancer. Last author DOI 10.1177/17562848231171456↗
  15. Combination immunotherapy for pancreatic cancer: challenges and future considerations. Last author DOI 10.1080/1744666x.2022.2120471↗
  16. Finding a role for cancer vaccines in pancreatic cancer: a model of resilience. Last author DOI 10.21037/hbsn-2021-26↗
  17. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2020.7328↗
  18. DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001819↗
  19. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  20. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: … Co-author DOI 10.1158/1078-0432.ccr-21-1789↗
  21. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  22. Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001563↗
  23. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectabl… Co-author DOI 10.1097/sla.0000000000004155↗
  24. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0099↗
  25. Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy. Last author DOI 10.18553/jmcp.2020.26.7.872↗
  26. The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1038/s41388-018-0553-0↗
  27. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Co-author DOI 10.1177/1758835919850367↗
  28. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenoc… Co-author DOI 10.1200/jco.18.01295↗
  29. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  30. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. First author DOI 10.1007/s00280-017-3494-3↗
  31. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. Last author DOI 10.1053/j.seminoncol.2018.05.004↗
  32. The role of the folate pathway in pancreatic cancer risk. Co-author DOI 10.1371/journal.pone.0193298↗
  33. Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. Co-author DOI 10.2147/cmar.s163475↗
  34. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience. Last author DOI 10.1097/coc.0000000000000115↗
  35. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  36. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2016.185↗
  37. Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Last author DOI 10.1080/21645515.2015.1093264↗
  38. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitab… Co-author DOI 10.1093/annonc/mdw006↗
  39. Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline. Co-author DOI 10.1093/annonc/mdw177↗
  40. Localized Pancreatic Cancer: Multidisciplinary Management. Last author DOI 10.1200/edbk_160827↗
  41. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Last author DOI 10.2217/imt.15.113↗
  42. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1200/jco.2014.55.7504↗
  43. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with meta… First author DOI 10.1634/theoncologist.2014-0394↗
  44. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Co-author DOI 10.2147/dddt.s60328↗
  45. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic ca… Co-author DOI 10.1016/j.ijrobp.2014.02.024↗
  46. Taxanes: impact on pancreatic cancer. Co-author DOI 10.1097/cad.0000000000000073↗
  47. Contribution of environment and genetics to pancreatic cancer susceptibility. Last author DOI 10.1371/journal.pone.0090052↗
  48. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  49. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. Last author DOI 10.1007/s11605-012-2064-6↗
  50. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Co-author DOI 10.1056/nejmoa1304369↗

Trials 1

  1. Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Principal investigator NCT02451553↗

Closest collaborators

The 25 strongest of 211 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rachael Ann Safyan · 6 shared papers, 2023–2026 · strength 1.65
  2. Andrew M. Lowy · 10 shared papers, 2014–2026 · strength 1.09
  3. David Bing Zhen · 6 shared papers, 2018–2026 · strength 1.06
  4. Andrew L. Coveler · 8 shared papers, 2015–2026 · strength 0.95
  5. Philip A. Philip · 7 shared papers, 2019–2024 · strength 0.93
  6. Howard S. Höchster · 7 shared papers, 2019–2026 · strength 0.89
  7. Davendra P. S. Sohal · 5 shared papers, 2020–2024 · strength 0.81
  8. Venu Gopal Pillarisetty · 4 shared papers, 2021–2025 · strength 0.74
  9. Sita Kugel · 3 shared papers, 2025–2026 · strength 0.66
  10. Dana Backlund Cardin · 6 shared papers, 2017–2026 · strength 0.65
  11. Muhammad Shaalan Beg · 4 shared papers, 2020–2024 · strength 0.58
  12. Andrea Wang‐Gillam · 4 shared papers, 2020–2024 · strength 0.58
  13. Vincent M. Chung · 6 shared papers, 2014–2026 · strength 0.57
  14. Sunil R. Hingorani · 4 shared papers, 2015–2026 · strength 0.54
  15. Syed Ameen Ahmad · 3 shared papers, 2021–2024 · strength 0.54
  16. Daniel D. Von Hoff · 8 shared papers, 2013–2020 · strength 0.53
  17. Christos K Fountzilas · 4 shared papers, 2019–2026 · strength 0.50
  18. Brian Matthew Wolpin · 6 shared papers, 2014–2026 · strength 0.50
  19. Andrew H. Ko · 6 shared papers, 2014–2026 · strength 0.45
  20. Gentry G. King · 2 shared papers, 2022–2023 · strength 0.42
  21. Jeffrey M. Hardacre · 5 shared papers, 2013–2026 · strength 0.41
  22. Brian G. Czito · 5 shared papers, 2014–2026 · strength 0.41
  23. Robert A. Wolff · 5 shared papers, 2014–2026 · strength 0.41
  24. Eric K. Nakakura · 5 shared papers, 2014–2026 · strength 0.41
  25. Mokenge Peter Malafa · 5 shared papers, 2014–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.